Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial
British Journal of Dermatology2015Vol. 173(4), pp. 930–939
Citations Over TimeTop 1% of 2015 papers
Kim Papp, Diamant Thaçi, Kristian Reich, Elisabeth Riedl, Richard G. Langley, James G. Krueger, Alice B. Gottlieb, Hidemi Nakagawa, Edward P. Bowman, Anish Mehta, Q. Li, Yijie Zhou, Richard Shames
Abstract
Tildrakizumab had treatment effects that were superior to placebo, maintained for 52 weeks of treatment, and persisted for 20 weeks after cessation. Tildrakizumab was generally safe and well tolerated. These results suggest that IL-23p19 is a key target for suppressing psoriasis.
Related Papers
- → Serum interleukin-30 level in patients with psoriasis and its correlation with psoriasis severity: a case-control study(2021)7 cited
- → INTERLEUKIN 23 AND INTERLEUKIN17 IN PSORIASIS, ATOPIC DERMATITIS AND LICHEN PLANUS: A SEROLOGICAL STUDY(2015)3 cited
- → Biological agents targeting interleukin-23/Th17 axis in inflammatory skin diseases: from basic research to clinical application(2022)1 cited
- → Mouse monoclonal antibodies at the red cell surface—I. Generation of EAC4 and interaction with C1(1985)1 cited
- → Research Progress of IL-17A Inhibitor in the Treatment of Psoriasis Induced or Secondary Skin Diseases(2022)